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Abstract The 2005 Report on Social Responsibility and
Health of the UNESCO International Bioethics Committee
(Ibc) proposes a new approach to implementing the right to
healthcare and suggests a number of Courses of Action to
be followed in various fields. Based on the latest available
data, we intend to present an overview of the current state
of European health systems in two of those fields—deci-
sion-making procedures and quality assurance in health
care—and to attempt a comparison of the situation with the
Report’s provisions, in order to pave the way for the
identification of what still has to be done to bridge inter-
national recommendations and the reality of policy and
practice in Europe’s health care.
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UNESCO
The Report on Social Responsibility and Health of the
International Bioethics Committee (Ibc) of UNESCO pro-
poses an innovative view of the problem of guaranteeing in
practice the standard of health in the terms it had been
previously formulated by the Universal Declaration on
Bioethics and Human Rights (UNESCO 2005). This
practical approach is best represented by the provisions
contained in Part V—Courses of Action, that describes five
domains in which action can be taken by health care sys-
tems to safeguard this standard of healthcare, and, in
particular, sets forth the principles by which theory should
be translated into action in accordance with the discussion
carried out in the previous sections (UNESCO 2010).
Two of these domains, decision-making procedures and
quality assurance, stand out for their comprehensive char-
acter, their intimate connection with the overall design of
the health system they are referred to and with the policies
guiding it, and above all their remarkable relevance to the
most recent and the ongoing developments of healthcare
reforms in Europe. Of the domains considered by the
Report, they represent the ones more directly related to the
design of health care systems in the traditional sense.
We intend to present an overview of the current status of
the systems and policies currently in place in Europe
concerning these two fields of action, so as to assess how
European countries currently compare to the principles and
the standards set by the Report, and to what extent their
implementation is already present in the debate over health
systems reforms, or rather requires to be upheld by pro-
moting a more clearly defined and a better recognized
definition of the right of healthcare in our continent.
Decision-making procedures
It should come as no surprise that ‘‘Decision-making pro-
cedures’’ is the opening topic of the section ‘‘Courses of
Action’’ of the Ibc Report. The difficulty of enforcing the
right to health care in its traditional definitions, and the
practical value of the distinction between civil and social
rights, stems exactly from the problem of the limited
availability of resources, which makes it necessary to
determine who is entitled to what.
This is why most European health systems have
designed legal and institutional frameworks that include,
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under different labels and using different procedures, but
with remarkable consistency, the definition of what is
variably referred to as the essential, or basic, or funda-
mental level of healthcare: quite simply, a ‘‘basket’’ of the
health care services guaranteed to either all of the popu-
lation (in a perspective of equality) or to different cate-
gories of patients in need of care (in a perspective of
equity).
Discussion of how this basic level of health care is
defined and ensured in different European countries
requires a preliminary consideration on the general orga-
nization and financing of health care in Europe.
European health systems are traditionally divided in two
categories, or models. The first model is known as
‘‘National Health System’’ model, or Beveridge model
(from Sir William Beveridge, the pioneer of the estab-
lishment of the British National Health System). Systems
belonging to this model ensure universal health coverage to
all citizens, and finance health provision through general
taxation. In these countries, the State usually has a major
role in the provision of health care as well, at least as far as
hospital care is concerned. In Europe, this is the model
followed by UK, Ireland, Spain, Portugal, Italy and the
Scandinavian countries. The second model, often referred
to as Bismarck model (from German Chancellor Otto
Bismarck), includes health systems in which health cov-
erage is not per se and a priori universal, but is linked to
payment of premiums to insurance funds that can be pri-
vate, public or any combination of the two, and operate
within a regime with different degrees of competition,
under the supervision of public authorities but without their
direct intervention in either the financing or the provision
of health care. This model or some variants of it are used in
Germany, the Netherlands, Belgium, France, Switzerland,
Austria, and in most Eastern European countries formerly
belonging to the Soviet bloc (Stevens and van der Zee
2008).
Traditionally, the Beveridge model is considered to be
more equal, but less efficient, because of lack of compe-
tition mechanisms, while Bismarck systems sacrifice the
guarantee of equality and universal coverage to the
advantages in efficiency provided by a more or less market-
based organization (which involves both funders and pro-
viders; Van der Zee et al. 2004). However, over the last
decades the differences between the two systems have been
increasingly blurred by waves of reforms that have com-
bined their features. Most Bismarck countries have now
enacted systems that ensure universal coverage and pro-
mote equality, while Beveridge systems have been intro-
ducing systems of managed competition which use quasi-
market mechanisms to exert pressure towards efficiency on
health care providers (Wagstaff 2009).
How the minimum level of care is defined
The notion of ‘‘health benefit basket’’, that is, the range of
medical services and pharmaceuticals guaranteed by the
health system, is in some cases only implicitly defined, by
formulas such as ‘‘all necessary medical services’’; in other
cases, it is defined explicitly through positive or negative
lists, including all goods and services which are respec-
tively covered or not covered by the national health system
or by basic primary health insurance (Paris et al. 2010).
A centrally-defined positive list is used in 8 countries to
define the benefit basket covered by the basic level of
coverage: they include many insurance-based systems
(Belgium, France, Luxembourg, the Netherlands, Poland
and the Slovak Republic) and two of the national health
systems (Italy and Spain). By contrast, a centrally-defined
negative list, containing the procedures excluded from the
benefit package, is used in four countries: the UK’s
National Health System and the insurance-based systems of
Germany, Switzerland and the Czech Republic. All other
countries, including the Scandinavian ones, do not explic-
itly define the benefit package, but may rather resort to
finely-tuned mechanisms to regulate decision-making pro-
cedures at the peripheral level (see below).
The regulation for pharmaceuticals provided is more
complex. Only Greece does not provide any lists; Germany
and the UK define the package for pharmaceuticals only by
negative lists, while the Czech Republic, Slovakia and
Iceland use both negative and positive lists. All other
countries use centrally-defined positive lists.
Lists are outlined by different institutions, the Ministries
of Health usually having a prominent role. Most of the
insurance-based countries involve the insurance funds in
the process.
Founding principles
A study conducted in 2006 by a Dutch advisory committee,
the Raad voor de Volksgezondheid en Zorg (RVZ), in the
setting of a large-scale reform of the Dutch healthcare
system, compared the approaches employed by different
countries to take decisions regarding prioritization and the
essential health care benefits to be guaranteed by the health
systems.
The most significant attempts were conducted by the
Scandinavian countries, and two cases are in this respect
emblematic. In Norway, a first attempt conducted in 1987
identified five criteria and fives groups of care in decreas-
ing order of prioritization, with a detailed listing of clinical
conditions. A follow-up carried out in 1997 simplified the
principles to three (patient’s health status, benefits of
interventions, equality) and the groups to four, but, above
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all, established a well-defined four-step process for all
future prioritization decisions, with key roles for scientific
and financial advice. In the neighbouring Sweden, a
Commission was set up in 1995 to establish a prioritization
mechanisms that complied with the principles set by the
1982 Health and Medical Services Act (Universality, Sol-
idarity, and Cost-Effectiveness), producing a set of three
principles: human dignity, necessity, and social solidarity;
and as many as two lists of hierarchically-organized patient
groups, one for resource-allocation and one for clinical
decisions. Interestingly, the commission explicitly refused
to recognize the principle of efficiency.
The RVZ study concluded that a wide consensus
appears to exist today as to the essential criteria that should
form the basis of prioritization of care to be paid by col-
lective means. While different terms are used, the recurring
notions are necessity, solidarity/justice, autonomy, effec-
tiveness and efficiency (Table 1), which are addressed one
by one by the RVZ as follows (Ottes and van Rijen 2006).
Necessity: Those with the highest needs have the highest
priority, where ‘‘need’’ is usually assessed by the acute and
life-threatening character of the condition. However, there
appears to be disagreements on the collocation of chronic
patients: Sweden tends to consider them in higher priority
than Norway and especially the Netherlands. Under the
pressure or rising costs, the tendency of explicitly men-
tioning those categories that are not covered by public
health care, e.g., the use of negative lists, has been
spreading. Where the line is drawn usually depends on the
interpretation of the notion of solidarity—basically, the
simple notion: the healthy pay for the sick. Clearly, it is not
unambiguous, and interpretations may significantly
diverge. In the Netherlands, the definition moves from the
counterpart of solidarity, that is, personal responsibility;
and it was suggested that all care outside hospitals belongs
to personal responsibility and is therefore, by definition,
outside the domain of solidarity (Commissie Structuur en
Financiering Gezondheidszorg 1987). The Swedes focused
on the notion of social solidarity, and therefore on attention
for the most vulnerable groups, while solidarity in the strict
sense was included in the domain of human dignity, with
the result that some criteria were explicitly named as in-
acceptable, such as age and personal responsibility—
which, in contrast, is counted by Norwegians among the
essential criteria. The RVZ observes that autonomy is
strictly related to the field of solidarity. The obligation to
subscribe the basic insurance limits the personal autonomy
of citizens, but it also increases it from the standpoint of
making treatments affordable to them that would not have
been otherwise. In the same way, prioritization itself is on
the one hand an obvious limitation of the autonomy of
those patients that are denied care, but on the other hand an
increase of the autonomy of those that are granted it.
Negative discrimination is never accepted, whether it be on
age, sex, race, ethnicity, social status and ‘‘own fault’’, but
some forms of positive discrimination (based, for instance,
on socio-economic background) are sometimes accepted.
However, the implementation in practice differs signifi-
cantly: sterility and sexual problems are given significantly
different priorities in different countries. Effectiveness is
everywhere a mainstay. A distinction between clinical
effectiveness and cost effectiveness must however be
drawn. The former refers to the assessment of the risk–
benefit ratio of medical procedures or medicines. For both
procedures and pharmaceuticals, these criteria can serve
two purposes: to assess whether ‘‘benefits’’ deserve col-
lective funding by basic primary health insurance (for
instance, drugs just improving the comfort of patients with
minor ailments can be excluded from basic benefits) or to
assess whether a procedure/product brings more benefits
than competing alternatives (comparative effectiveness
assessment). Unlike clinical effectiveness, cost-effective-
ness assessment requires economical techniques to com-
pare incremental costs and benefits of therapeutic
alternatives. Since this method is a quantitative one, it
gives numerical outcomes, so clear cutoffs can be defined
beyond which procedures or products are not covered: this
is what happens in the United Kingdom and in Sweden. In
Sweden, the 1982 Health and Medical Services Act even
includes ‘‘Cost-Effectiveness’’ among the three funding
Table 1 Recurring principles in decision-making for healthcare
Necessity Priority is given to those with the highest need (Ottes and van Rijen 2006)
Solidarity Priority is given to the most disadvantaged in society, so that the healthy pay for the sick (Ottes and van Rijen 2006;
Hoedemaekers and Dekkers 2003)
Autonomy Self-determination that is free from both controlling interferences by others and personal limitations preventing
meaningful choice (Miller-Kean Encyclopedia and Dictionary of Medicine 2006)
Effectiveness Extent to which the intervention in question produces the desired effect (Maxwell 1992; Witter and Ensor 1997)
Efficiency Extent to which objectives are achieved by minimizing the use of resources (WHO 2000)
Discrimination Treating individuals differently on the basis of their properties of them (Lippert-Rasmussen 2006)
Affordability or budget
impact
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principles of the that are stipulated to inform the provision
of health care, the other two being ‘‘Equality’’ and ‘‘Soli-
darity’’. However, it is on the third place of the hierarchical
order the three principles are expected to be considered in
policy-making and in decision-making concerning health
care.
Along with effectiveness, appropriateness is almost
always mentioned, despite not being indicated as the most
important criteria in any country.
Significantly, affordability or budget impact has been
explicitly mentioned and clearly formalized only recently
in the health policies of European countries, which could
reflect a progressively increasing acceptance of the legiti-
macy of allowing cost constraints to influence provision of
health care. Most countries still do not explicitly mention
affordability among coverage decisions: Austria, the Czech
Republic, Denmark, France, Germany, Italy, Portugal,
Spain, Sweden, and Switzerland. Three countries, however,
have run into the opposite extreme, by mentioning
affordability as the single criteria for reimbursement
decisions: Ireland, Greece, and Turkey. The Greek law
even goes to the length of explicitly stipulating that cov-
ered benefits are defined by available funding resources.
From principles to process
Informal and implicit criteria seem to be bound to play a
significant role in decision-making, and several reasons
have been proposed for this: the political nature of the
process, so that an acceptable compromise must be usually
found between scientific and professional approval and
social approval (Klein 1998); the liability to different
interpretations when it comes to implementing criteria,
even after they have been established; the unavoidable
biases and assumption that always exist at the basis of the
very scientific research that should represent the firmer
basis of these decisions, especially as regards those tech-
nologies that are less liable to objective evaluation (Berg
et al. 2004).
The recognition of the problems intrinsic to formulate
and applying clear-cut criteria in forming benefit baskets
has heavily influenced policy-making. Based on the RVZ’s
observations, a conspicuous trend can be detected when
analyzing the historical evolution of the attempts to devise
ethically sound procedures for the composition of the
health benefits basket. The earliest ones, mainly those
conducted in the late 1980s and in the early 1990s in the
Scandinavian countries (Health Care and Medical Priorities
Commission 1993; Calltorp 1999; Norheim 2003), went for
a so-to-speak ‘‘top-down’’ approach: they drew specific
criteria from general principles. In contrast, later attempts
(Holm 1998; Swedish Parliamentary Priorities Commission
1995; Berg and van der Grinten 2003; Rawlins 1999; Sabik
and Lie 2008), rejected this ‘‘mechanistic’’ approach: rather
than trying to operate based on fixed principles and pre-
determined standards, they emphasized the procedure by
which prioritization occurs, and the need to ensure that the
procedure itself complied with ethically consistent criteria.
This progressive shift in focus by policy-makers has
mirrored a similar development in the international debate
in the same field. The formulation of rules that control the
process of decision-making itself (Holm 1998) and the
proposal of practical approaches to allocation of resources,
such as Daniels’ ‘‘Accountability for reasonableness’’
(Daniels 2000), had indeed already made the simplistic
principle-standard approach outdated.
As a result, the goal of ‘equity and quality in the creation
and delivery of health-related services’ set by the Report
appears to be a realistic one: European policymakers have
already moved in that direction.
Public participation and stakeholder perspective
An important consequence of the ‘process approach’
involves public participation. In the Netherlands, the 1991
Dunning commission proposed a set of principles for the
choice of the essential benefits (Commissie keuzen in zorg
1991): first, a division into categories that allows all citi-
zens to have access to the same services; second, choices
should be as much as possible explicit rather than implicit
and public responsibility should be taken for them; third, in
the composition of the basket, along with professional and
scientific arguments, social values should be taken into
account. Moreover, the commission set four principles:
necessity, effectiveness, efficiency, and individual respon-
sibility. While the second and the third principle pertained
to the domain of quality, and required the establishment of
a systematic evaluation procedure such as Health Tech-
nology Assessment, the first and the fourth principles
represented an explicit appeal for a broader involvement of
relevant actors, that is, the subjects involved in some way
in the health care system (Bal and van de Lindeloof 2006).
This recommendation found a follow-up in the 2003 advise
‘‘Outlines of the basic basket’’ by the Gezondheidsraad that
remarked that ‘‘the application of the criteria always
requires a finely-tuned (genuanceerd) approach’’, with a
recognition that the decision whether to include or not a
provision into the basket ultimately depended not only on
scientific considerations, but also social, juridical and eth-
ical ones (Gezondheidsraad 2003).
The reasons why participation of citizens in decision-
making is advocated are numerous: to comply with the
democratic principle that everybody should participate in
decisions that ultimately affect them (Hansen 2000; Dan-
iels 2000); to increase the quality of the decision-making
process (also by creating a connection between different
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types of knowledge and experience, thus preventing hostil-
ities between them; Harrison and Mort 1998; Charles and
DeMaio 1993); to reduce political hostility and increase
compliance (Goetz and Gaventa 2001; Wiseman et al. 2003;
Daniels 2000; Rowe and Shepherd 2002; Mossialos and
King 1999). In contrast, opposition to public participation
also uses diverse arguments: the lack of knowledge on the
part of the general public, with the danger that interest groups
or distorted information make their way into the decision-
making process (Harrison and Mort 1998; Mossialos and
King 1999; Edgar 2000); public can be manipulated to hinder
politically difficult decisions (Harrison and Mort 1998); and
the public might actually not desire to be involved in the
decision-making process, having already delegated others to
take such decisions according to the principles of represen-
tative democracy (Harbers 1996).
Based on existing studies (Tenbensel 2002; Bal et al.
2002), the RVZ report distinguishes between deliberative
and non-deliberative methods, the former being charac-
terized by every part being able to express its view in an
attempt to change the other part’s opinion or clarify it, the
latter using mediation roles to exchange information, and
without any intention to change others’ viewpoints. The
‘‘focus group’’ is an intermediate form, as it includes a
deliberative stage, but the viewpoints are presented by a
mediator. Also, some methods address the public as
patients, other as citizens. It is apparent that the former
definition entails their representation of a more particular
interest than the latter, and that these two approaches can
lead to differently oriented contributions. But, above all,
methods vary as to the decision power that is bestowed
upon the public: a widely used classification (Charles and
DeMaio 1993) distinguishes ‘‘consultation’’, where partic-
ipants can only express their view to those that will ulti-
mately decide, ‘‘partnership’’, typical of the committees
where decisional responsibility is shared more or less
equally by all participants, and ‘‘dominant responsibility’’,
where the opinions of the participants are directly con-
verted into decision (e.g., in referenda). Of course, in
practice more forms of public participations can co-exist in
the same system, or in different stages of the same process,
giving rise to mixed forms.
Public involvement at the highest levels of decision-
making and health prioritization is still not common in
Europe. Recent data show that patients are represented in
decisions pertaining to the licensing of pharmaceuticals
only in the Czech Republic, Denmark and Sweden, while
they are represented in decisions relating to the coverage of
health services in the Czech Republic, Denmark, the
Netherlands, and Switzerland (Paris et al. 2010). In all
other countries, they have no involvement or only a mar-
ginal one, with no significant responsibility in decision-
making.
The effect of financial pressure
If we leave the field of principles and go on to consider the
practical factors that appear to influence the actual scope of
benefits guaranteed, it becomes plain that the evolution of
the former has been heavily affected by the development of
the latter.
Since the definition of the structures of most European
health systems after the Second World War, health costs
have been increasing steadily. With regard to high-income
countries (which all European countries are), the main
factors on which responsibility for this trend is blamed are
demographic changes leading to population ageing (with
increased co-morbidity), advances in technology with
introduction of increasingly expensive equipment, and
growing expectations on the part of the population on the
efficiency and the quality of care.
It is therefore not surprising that cost containment fig-
ures prominently in the agenda of health care policymak-
ers. The first consequence of cost pressures is indeed the
increase in health care institutions’ deficits; other common
consequences are also purely financial, with no significant
impact on health care delivery itself, e.g., partial refunds
from health care providers and/or the pharmaceutical
industry to health insurance funds or the government, or
reductions in physician fees.
However, increase of out-of-pocket payments has today
become the most widely employed measure to address
increased costs, which has been considered one of the most
worrying trends in European health care policy of the last
two decades, because of its impact on access to health care.
Out-of-pocket payments increase the exposure of house-
holds to financial losses associated with health care, pre-
venting which should be one of the main goals of health
systems. Significant evidence exists on the undesirable
effects of user charges in this respect (Robinson 2002). The
RAND Health Experiment, conducted in the United States
in the 1970s, found that while higher cost-sharing
decreased utilization, this phenomenon involved at the
same time effective and ineffective or inappropriate pro-
cedures, and that higher cost-sharing was also associated
with lower health status (Newhouse 1993). These unde-
sirable effects from the utilitarian viewpoint were also
shown to be accompanied by negative effects on equity, as
decreased access to effective interventions seems to dis-
proportionately affect lower-income groups, children, the
unemployed and the homeless, both in high-income (Rubin
and Mendelson 1995; McLeod et al. 2011) and in devel-
oping countries (Schieber and Maeda 1997), and avail-
ability of health services requiring payments appears to
represent one of the major preconditions for catastrophic
financial payments in different country settings (Xu et al.
2003).
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Lastly, direct effects on the level of care are reported
increasingly often: in recent years, waiting times for a
number of services increased in many Eastern European
countries, while delisting of goods of services from the
health benefit package was reported in Belgium, Czech
Republic, France, Germany and Italy (Paris et al. 2010).
The effect of market mechanisms
Along with constraints originating from increased costs,
trends in reform of the structure of health care systems
themselves appear to be severely affecting the ‘‘essential
care’’. This is especially notable in countries with Bismarck
systems, that have been undergoing more and deeper-
reaching reforms than Beveridge countries over the last
few years (Hassenteufel and Palier 2009).
Among the countries with an insurance-based system,
three, France, Austria and Greece, have introduced a long
series of reforms pressing for greater equality, transforming
their systems into de facto national health services. Citi-
zens are automatically assigned to an insurance fund based
on their job, which means that there is no real competition
between insurers. Still, there is divergence in how the
‘‘essential care’’ is defined: at one extreme, Greece, where
insurers determine themselves benefits, level of coverage
and contribution rates. At the other one, France, where
contributions and benefits are uniform and determined by
state laws. Halfway between them is Austria, where
insurers are required to cover ‘‘all necessary services’’, but
these are not explicitly defined, leading to variations across
health insurance funds.
The remaining five countries with systems based on
multiple insurance funds have a true competition between
insurers, because citizens are allowed to choose their insur-
ance fund. How the ‘‘basic benefit’’ provided by insurers is
defined, however, varies from country to country. In Slova-
kia, both contributions and benefits are uniform, and com-
petition is supposed to rest solely on quality of care. There is
a somewhat greater flexibility in the Czech Republic, where
insurers are required to offer a uniform benefit basket defined
by law, but they are allowed to extend the scope of coverage
but not to alter premiums or the level of coverage (percentage
of the costs paid by the insurer). In Switzerland, a uniform
benefit basket is also defined that cannot be modulated by
insurers, but lower premiums can be offered to those enrol-
lees that accept ‘‘managed care plans’’ or higher cost-sharing
(Leu et al. 2009).
The health systems of the Netherlands and Germany
underwent in recent years carefully designed reforms aimed
to maximize competition and market-based mechanisms,
also by raising the flexibility of the benefits basket, while at
the same time ensuring universal coverage and counterbal-
ancing market failures. In the Netherlands, insurers can
modulate the basic benefit basket set by the Government only
by adding more services, and not by removing or replacing
the standard ones. They have also significant room for
competition on costs: premiums may vary by type of contract
(single vs. collective; collective for single employers or by
consumer groups) and by coverage model (in-kind benefit vs.
reimbursement). In Germany, a reform that entered into
force in 2009 grants funds extreme flexibility in the defini-
tion of the benefits covered: higher benefits in exchange for
higher cost-sharing or acceptance of a set of constraints, such
as restricted provider network, or specified health care
pathways; same benefits, lower premiums but higher cost-
sharing; no-claim bonuses (financial advantages for those
who do not seek care for a certain time). If the insurance fund
has a financial surplus, additional benefits or premium
rebates are allowed; if the fund has a financial deficit, it is
compelled to charge their enrollees an additional premium
(Cheng and Reinhardt 2008).
These five systems have therefore been granting their
insurance funds a constantly increasing number of instru-
ments variably defined as ‘‘levers’’ to ‘‘steer the demand
for health care’’ or ‘‘ensure appropriate use of the health
services’’. While the use of such instruments appears
consistent with the market approach, it should not escape
our notice that their introduction has ethical implications
that go well beyond their effects on competition and effi-
ciency. Such instruments entail an explicit trade-off
between, on one hand, the costs paid by the citizen, and, on
the other hand, the number of benefits, the frequency of
recourse to health care, and the choice of providers or
health care pathways—in short, the provision of health
care. In other words, financial advantages are increasingly
given a value in terms of sacrificed health care, at least as
long as the non-compulsory component of healthcare
insurance—which has a different weight from country to
country and never includes, of course, the basic package—
is concerned. Acceptance of this trade-off equals to the
implicit admission that not all health care is guaranteed as
such, but that the provision of at least a part of it is in some
way related to the money every citizen is willing to spend
on it. As a result, the extensive provisions these States
introduce to ensure a minimum level of health care for
everybody only appear to ensure some level of care for
everybody. What care each citizen actually affords is
unclear, lost as it is in tangle of insurance policies provi-
sions and State regulations and limitations (Maarse and
Paulus 2003).
The coverage of the ‘‘average’’ citizen
The above discussion makes it easy to understand why it is
difficult to analyze the actual level of health care guaran-
teed as basic or essential: the details of insurance policies,
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State interventions, financial mechanisms make it possible
for significantly different levels of health care to be pro-
vided to different groups of people within the same coun-
tries, both in terms of scope of coverage (which benefits are
provided) and depth of coverage (which percentage of
costs of each benefit is covered). An attempt can be made,
however, to evaluate the health care benefits guaranteed to
the ‘‘average’’ citizen of each countries (Paris et al. 2010).
On the whole, most countries guarantee a high level of
coverage for acute inpatient care and medical services, as
well as for laboratory tests and diagnostic imaging. In
France, the share of costs covered for outpatient physi-
cians’ services is 60%, bur complementary health insur-
ance, held by 92% of the population, covers virtually all
cost-sharing. In Ireland, basic primary health insurance
does not cover primary care services for people eligible for
Category II (the wealthiest two-thirds of the population).
Pharmaceuticals are usually covered at lower levels than
other health services. Only in Italy and the Netherlands
does coverage of pharmaceuticals reach 100% of costs: the
Netherlands, Italy and the United Kingdom, even if
mechanisms of cost-sharing partially distort this provision
in the latter two countries.
At the bottom of the ‘‘hierarchy of services’’ are dental
care and eye products, covered in most cases at a lower
level than all other types of care or not covered at all.
It should be considered, however, that what is theoreti-
cally covered by basic health coverage is distorted by limi-
tations to access to care that only become evident in practice.
For instance, people may be entitled to health services ‘‘free
at the point of care’’ but nevertheless be obliged or tempted to
turn to private providers with copayments or to lay out
informal payments for different reasons (lack of supply, long
waiting times). For instance, in Belgium, patients pay extra-
billing and supplemental fees for inpatient care leading to
high levels of private payments (23.8%), exceeding ‘‘offi-
cial’’ copayments (Lecluysea et al. 2009). A similar phe-
nomenon occurs in Hungary, where hospital and primary
care should in principle be fully covered by basic health
insurance. On the other hand, in many countries the actual
level of private funding is below the level predicted by cost-
sharing arrangements; this happens because some population
groups benefit from partial or total exemption of cost-sharing
requirements.
Quality assurance
While no policy-maker or health professional would ever
refrain from confirming their support to initiatives aimed to
ensure and increase quality in health care, a shared definition
of what we actually mean by quality does not exist. Different
European countries and, within them, different institutions
and interventions confer on this word a variety of meanings,
which need to be carefully taken into account as we consider
what quality assurance policies are currently adopted.
The most widely accepted definition of ‘‘quality’’ is the
one given by the Institute of Medicine in the United States
in 1990, which reads as follows: ‘‘the degree to which
health services for individuals and populations increase the
likelihood of desired health outcomes and are consistent
with current professional knowledge; IOM 1990). It is
remarkable that this definition mentions both individuals
and populations as the addressees of health services, and,
above all, that their ‘‘desires’’ are mentioned, which reflect
acknowledgement of the central role played by the values
and the expectations of those interested and involved in the
performance of the health system.
While this definition is carefully designed, attempts to
implement and pursue the notion of quality in practice
require it to be broken down into components more liable to
be referred to visible actors and activities—the so-called
dimensions of quality. A study by the European Observatory
on Health Systems and Policies (Legido-Quigley et al. 2008)
has found quality to be defined by a variable array of
dimensions including effectiveness, the ability of a certain
care measure or intervention to result in the intended effects;
efficiency, that is, the ratio between output and input; access,
the extent to which those in need of care can actually obtain
it; safety, the reduction of risks associated with the measure
or intervention itself (medical errors, side-effects of medi-
cines); equity, the availability of the same services to
everybody, with the possibility of grading the intensity of
care based on the degree of need or the ability to benefit from
care (Whitehead 1991); appropriateness, the correspon-
dence between the intervention and the needs of the patient;
timeliness, provision of the intervention in an adequate time;
and responsiveness to patients, one of the dimensions most
variably defined, but of particular interest here, because it
usually includes the acknowledgement of patient’ and soci-
ety’s preferences and values.
Article 86 of the Report specifies the requirements of
quality assurance in health care in the following terms: ‘‘(1)
adequate prevention and/or treatments, based on sound
evidence, are applied at right time; (2) primary or sec-
ondary harm are avoided or reduced; (3) patient dignity and
rights are respected’’. Accordingly, the elements of quality
that more directly referenced are Effectiveness, Appropri-
ateness, Timeliness, Safety and, and Responsiveness
(sometimes referred to as Patient-Centredness).
From the international level to the national level
As we go on to summarize how these dimensions are
pursued in practice, we have to first remark the attention of
international organizations on this matter. One of the first
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frameworks on quality of care specifically regarding Europe
was provided by the Council of Europe with the Report
‘‘Dimension of Quality Improvement Systems’’ (Council of
Europe 1997). That report triggered a number of initiatives,
mainly at the level of the European Union, which included
the issue of quality in the 2000 Health Policy by advocating
the diffusion of best practices (Shaw and Kalo 2002). In
2008, the European Commission presented a number of non-
legislative proposals pertaining to the quality of health care,
among which the Recommendation on Patient Safety and
Quality of Health, which explicitly states as its goal that of
providing the necessary and relevant practical and legal tools
and mechanisms for the Member States, as well as the key
stakeholders, to take appropriate actions to improve safety
and quality of care (European Commission 2008).
On the national level, several strategies exist. Oevretveit
(2001) and the 2008 Report of the European Observatory
of Health Systems and Policies (Legido-Quigley et al.
2008) distinguish three levels at which policy development
in the field of quality takes place: the health system level;
the organizational level; the level of services.
Health system level strategies
At the level of health systems, the most obvious type of
intervention is the introduction of legislation and the ini-
tiation of policies especially directed to the quality of care.
Legislative activity is, however, quite heterogeneous,
probably also as a consequence of differing views about
formal legislation, rather than more decentralized instru-
ments such as negotiations or agreements, being the most
suitable tool to this end. In general, lack of systematic
legislative approaches to quality assurance is mainly
notable in Eastern European countries, with some notable
exceptions such as Czech Republic with its National
Quality Policy, adopted in 2000 (Health Systems in Tran-
sition. Czech Republic 2009). Countries with a longer
history of membership of the European Union already have
long-standing strategies in place of which Sweden with its
1990 National Strategy on Quality is the most significant
example. In the other countries, approaches seem to differ:
while dissemination of guidelines seems to be common
everywhere, France focused on training and accreditation,
Germany progressively shifted from a system based on
professional self-regulation to legal obligations to intro-
duce quality management programmes and quality indi-
cators, while Spain and Italy have been gradually
delegating quality management (along with several other
responsibilities) to Regional governments, which led to yet
more fragmentation. A small group of countries, namely
the United Kingdom, Denmark, the Netherlands, Austria
and Belgium, are envisioning substantial reforms that
mainly follow the ‘‘top-down’’ approach—possibly also as
a consequence of evaluation of previous ‘‘bottom-up’’
strategies, like the 1993 National Strategy for Quality
Improvement in Health Care in Denmark, that led to a
number of initiatives that were largely local, ad hoc and
informal (Legido-Quigley et al. 2008).
Policies on patient safety in Europe recognize a pioneer-
ing role in the 2001 UK NHS Report An organization with a
memory (Department of Health 2000), and by recommen-
dations on patient safety issued in 2005 by both the EU and
the Council of Europe (Legido-Quigley et al. 2008; Council
of Europe 2006). The most remarkable ones are the Danish
system, based on a confidential, non-punitive but mandatory
system for reporting adverse medical events, collected in a
national database, and the British one, coordinated by the
National Patient Safety Agency mainly operating with
management of information on adverse event (also by means
of Confidential Enquiries) and with subsequent interven-
tions, including alerts and confidential advice.
Patient safety was the primary concern in the develop-
ment of the well-refined regulations on the approval of
pharmaceuticals and medical devices, the former being
approved either by the European Medicines Agency
(EMEA) or by Member States, the latter being regulated by a
number of EC Directives and through national legislations.
The label registration and licensing is used to refer to
the activities aimed to ensure that health professionals or
health care providers meet minimum standards of compe-
tence. They therefore include activities such as training,
registration, certification and revalidation. While there is a
striking variability and lack of coordination in the training
of professionals across Member States, the problem has
been made more compelling by increasing attention on the
issue of mobility of professionals across Europe and the
need for mutual recognition of professional registration. A
number of innovative approaches have been attempted in
this field: one is the instrument of medical revalidation, a
regular, compulsory review of the competences of profes-
sionals, necessary for renewal of the permission to practice.
The introduction of quality of care in the setting of the
education and training of medical professionals has also
been attempted, but only in a sparse and fragmented way,
on the initiative of diverse subjects (public authorities,
government agencies, professional associations, single
universities) and implemented to variable degrees.
The most systematic—and probably most promising—
approach to quality assurance at the level of health systems
is Health Technology Assessment (HTA), a methodology
to evaluate the conditions for and the consequences of
using any health technology, that takes into account four
dimensions—the technology, the patient, the organization
and the economics (DACEHTA 2007). The main advan-
tages of HTA are its quantitative basis, which allows for
standardization and comparability, and its global scope,
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that accounts for all of the stakeholders of health care.
Nevertheless, the label of HTA is used with a variety of
meanings, and its application varies from unsystematic to
well-developed, the pioneers being Sweden, Netherlands,
France, Germany, Belgium, Denmark, UK, Spain, Italy
(the latter two countries displaying no unitary national
policies for HTA because of their regionalized structures,
but still counting a good number of institutions and ini-
tiatives active in this field).
Organizational and service level strategies
Organizational quality assessment schemes evaluate the
providers of health care on an either voluntary (in which
case they are usually carried out by private subjects, in
most cases professional organizations) or compulsory
(usually by public authorities or agencies) basis. This dis-
tinction entails a difference in approach: voluntary
assessments are oriented to self-development and
improvement, while compulsory assessment has a more
judgmental, standard-oriented character. Two popular
models of organizational quality assessment originated in
an industrial setting, but were later applied to health care
by the private international organization owning them. The
International Organization for Standardization ISO 9000
model series is devoted to healthcare; along with countries
where it is popular as a basis for voluntary accreditation,
there are cases of countries that have used ISO standards as
a model to develop their own public, compulsory accred-
itation criteria: they include the Netherlands (since 1994),
Finland, and Spain. The European Foundation for Quality
Management (EFQM) model has a different perspective, as
it is oriented to improvement and the pursuit of excellence
in customer and employee satisfaction, giving providers the
tools for quality management and continuous improvement
rather than evaluating their adherence to pre-set standards.
It is, however, less commonly used than the ISO model in
the health care sector.
The level of clinical quality assurance is undoubtedly
dominated by clinical practice guidelines, the traditional
instrument designed to improve clinical practice. Corpo-
rations of health professionals are usually called upon in
this process, as the traditional autonomy of physicians
poses difficulties for attempts to influence their profes-
sional behaviour by constraints (Hulst 1999). This also
represents the key weak point of this approach: evaluating
adherence to guidelines is difficult, as is assessment of their
effectiveness in influencing quality. Again, we stand before
a fragmented situation (Shaw et al. 2010). On the one hand,
this type of instrument is so mature that it has given rise to
international frameworks (Council of Europe’s Guideline
Recommendation 2001; Guidelines International Network
2007), and, above all, to some impressive achievements.
The method of peer review or visitation is based on on-
site surveys conducted by medical professionals, who
therefore assess the organizational features and the activity
of care provided by fellow physicians and health profes-
sionals, and advise them on how to improve (ExPeRT
1998). This model is not widespread, but in what countries
it exists it has been integrated into the set of regular,
compulsory activities.
A number of approaches exist that are focused on col-
lection and management of information. Availability of
transparent data on quality is considered as a means to
enhance quality and efficiency (Canadian Health Services
2006), even in the absence of control mechanisms. In most
European countries, information on quality of services
supplied by individual providers is available, but different
aspects are monitored in different countries, with a prom-
inence of data on hospitals and a relative lack of data on
primary care. In the Netherlands and in Slovakia, insurers
and the media (in Slovakia, also the government) publish
information on clinical outcomes, use of appropriate pro-
cesses, patient satisfaction and patient experience. A par-
ticular type of information is represented by surveys of
health care users and the public, which, however, lack of
systematic implementation, with some few exception at the
international (the Eurobarometer series) and at national
level (like the National Survey of Patient and User Expe-
rience in the UK). Most other experiences are one-off
initiatives; still, it should be observed that Eastern Euro-
pean countries have displayed a remarkable liveliness over
the last few years: well-organized patient satisfaction sur-
veys have been carried out in a number of Eastern Euro-
pean countries (CPSS 2007).
Lastly, a promising approach is represented by the use
of quality indicators. While setting up this kind of proce-
dure is difficult from both the organizational and the
financial standpoint, what countries have used this has done
so with success. Denmark’s National Indicators Project
(Health Systems in Transition. Denmark 2007), Germany’s
national system for performance measurement of medical
and nursing services in hospitals (BQS 2007) and the
national health care quality registers of Sweden deserve to
be mentioned in this respect.
How does this landscape compare to the recommenda-
tions contained in the IBC Report? Two points stand out
clearly. The ‘‘international cooperation’’ the Report calls in
for better ‘‘information and training to clinicians, agreed best
practice guidelines’’ (Art. 85) was poorly developed in the
1990s, but the recent tendency for the internationalization of
guidelines demonstrated by the 2001 Council of Europe’s
Guideline Recommendation and the GIN and by the publi-
cations of the Council of Europe and the EU on patient safety
is promising in this respect. The diffusion of HTA appears to
be an adequate response to the Report’s warning on the
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Table 2 Historical landmarks and open problems of approaches to quality assurance in Europe
Strategies Landmarks Open problems
Health system level
National legislation or
policy for quality
1990 Sweden: National Strategy on Quality
1993 Denmark: National Strategy for Quality
Improvement in Health Care (Health Systems in
Transition. Denmark 2007)
2006 Netherlands: experience from the 1993
Individual Health Care Professions Act (BIG) and
the 1996 Care Institutions Quality Act (KZI)
embedded in the 2006 health care reform (Health
Systems in Transition. The Netherlands 2009)
Persisting West-East divide; Czech
Republic, Slovenia, Lithuania
recovering
Specific institutional
structures to ensure
patient safety
2001 UK: NHS Report An Organization with a
Memory; establishment of National Patient Safety
Agency
2004 Denmark: the Patient Safety Act includes a
database collecting mandatory reports of adverse
medical events (Health Systems in Transition.
Denmark 2007)
2005 EU and Council of Europe independently issue
recommendations on patient safety
In 2005, only the UK, Denmark, the
Netherlands, Germany and Spain had
set up specific institutional structures for
patient safety (Somekh 2007)
Approval of
pharmaceuticals and
medical devices
1995 EU: foundation of the European Agency for
the Evaluation of Medicinal Products, later
European Medicine Agency (EMA)
Registration and
licensing; revalidation
1993 Netherlands: the BIG (Individual Health
Professions Act) activates medical revalidation
2008 UK: The Report of the Chief Medical Officer
for England’s Working Group sets the principles
and next steps for implementing revalidation in the
UK
Quality in training and
education
1995 Belgium: the RIZIV-INAMI (National Institute
for Sickness and Disability Insurance) introduces a
system of voluntary accreditation for physicians
and dentists including training for the promotion
of quality of care (Health Systems in Transition.
Belgium 2010)
1996 Sweden: The SALAR (Swedish Association of
Local Authorities and Regions) starts initiatives to
promote the integration of quality into health
professional education at all levels
Health Technology
Assessment
1991 United Kingdom: the Department of Health
publishes the report on Assessing the effects of
health technologies (Department of Health 1991)
2006: Launch of EUnetHTA (European Network for
Health Technology Assessment)
Persisting West-East divide
Organizational and services level
Organizational quality
assessment schemes
1987: First publishing of the ISO 9000 series
1988: Initiation of the EFQM frameworks by 14
representatives of European multi-national
companies, the European Commission and the
European Organization for Quality.
Clinical guidelines 1988 Finland: the Finnish Medical Society produces
the first electronic guidelines for primary care
(Kunnamo 2005)
1999 UK: creation of National Institute of Clinical
Excellence (NICE)
2002 Germany: translation of clinical guidelines into
the National Disease Management Programme.
(Ollenschlager and Kopp 2007)
392 L. Valerio, W. Ricciardi
123
danger of ‘‘drugs and techniques of uncertain efficacy and
unclear adverse event profiles’’ and call on ‘‘research on
effectiveness’’. The diffusion of quality assurance practices
and the main historical landmarks in the process are sum-
marized, respectively, in Table 2 and Fig. 1.
Definition and enforcement of patients’ rights
Quality is almost always mentioned in documents and law
provisions specifying patients’ rights. In most European
countries, patients’ rights are formally defined in some way
at the national level, except for Ireland, Sweden and
Switzerland. In most countries (but, notably, not always in
central-northern Europe), an obligation exists for hospitals
to have a patient desk to register patients’ complaints, and
all except Denmark and the Netherlands have an
Ombudsman investigating patients’ complaints.
It has been observed that a requirement for guarantees
on patients’ rights and guidelines to effectively exert
pressure toward quality is the possibility of suing them as
basis for legal action, in the form of a torts system or class
actions (Hulst 1999). In this respect, in all countries but
Finland, Iceland and the Slovak Republic, patients can seek
redress in courts in case of medical errors, and almost
everywhere class action is possible against health providers
and pharmaceutical companies. Denmark is an extreme
case, in that health providers’ liability does not even have
to be proven to grant indemnification to the victim, but can
be ‘‘presumed’’ under certain conditions. There is also a
Fig. 1 Diffusion of approaches to quality assurance in health care in
the EU-27. The diagram shows the number of countries adopting each
approach to quality assurance in healthcare. Approaches to accred-
itation lack homogeneity and cannot thus be compared. Source
Authors’ elaboration from Assuring the Quality of Health Care in the
European Union. A Case for Action. European Observatory on Health
Systems and Policies 2008
Table 2 continued
Strategies Landmarks Open problems
Quality indicators 1999 Denmark: establishment of the National
Indicators Project (www.nip.dk)
2000 Germany: foundation of the BQS-Instituut
(Institute for Quality and Patient Safety) by
insurances and multiple healthcare-related
government agencies (BQS 2007)
Peer review or visitation 1967 Netherlands: first introduction of the
‘‘visitatie’’ model in teaching hospital (Klazinga
2000)
1980s Netherlands: frameworks for visitation
developed by associations of specialists
2011 Netherlands: visitation becomes compulsory
for General Practitioners
Only used in the Netherlands, UK and
Slovenia
Surveys on health care
users and the public
1973: The European Commission sets up the
Eurobarometer as a means of conducting surveys
of public opinion.
2002 UK: the Department of Health initiates the
National Patient Survey programme
(www.nhssurveys.org)
Eastern Europe (Poland, Slovakia,
Slovenia, Romania) displaying
dynamism (CPSS 2007)
Source: Authors’ elaboration on Assuring the Quality of Health Care in the European Union. A Case for Action. European Observatory on Health
Systems and Policies 2008
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basis for ‘‘no fault compensation’’ in a number of countries,
including Austria, France and the Scandinavian countries:
patients may obtain compensation even when the adverse
outcome was not predictable according to the state of
medical knowledge.
The attempts to include patients’ representatives at the
decision-making level has involved the field of quality as
well, but is still an exception. Patient are represented in
health technology assessment bodies in Australia, Den-
mark, Norway and the United Kingdom; in hospital plan-
ning in Denmark, Iceland, Norway and the United
Kingdom and in the definition of public health objectives in
Denmark, France (through regional consultations on public
health), Hungary, Iceland, Norway, Portugal, and the
United Kingdom. The significance of involvement of the
public in processes pertaining to quality assurance can be
better appreciated if two aspects are considered. From the
legal and ethical standpoint, with a view to ensuring the
right to health care, it represents the only possible solution
for the proper consideration of all sectors of society, as
well as for shifting to the stakeholder approach in health-
care. From the practical and technical viewpoint, with a
view to maximizing the health status and patient satisfac-
tion, it has been observed that a variation exists across
cultures as regards what is ‘‘important’’ in healthcare: a
further confirmation that solving the problem of what is
quality requires individual values to be taken into account
(Groenewegen et al. 2005).
Do these provisions match the Report’s calls for ‘‘pro-
tection of patient rights and dignities’’ (Art. 85) and the
‘‘cooperation of all institutions and members of society’’ to
improve ‘‘the quality of health care systems’’ (art. 88)? A
comparison of the approaches to quality described here with
the dimensions of quality addressed by the Report (see
above) suggests that these policies might not be sufficient.
The most developed strategies still seem to be in fact those
that embrace a notion of quality as effectiveness and cost-
effectiveness, and that can thus be referred to an utilitarian
ethical framework, while those that reflect a communitarian
approach—such as the inclusive and collective character of
decisions—or a liberal one—such as provisions to ensure the
respect of individual freedom—are still limited; yet, a ten-
dency of development in the latter direction does seem to
exist.
Conclusion
Over the last two decades, the European health systems
have shifted from the problem of ensuring health care to
everybody to the problem of determining what health-
care—in scope and in depth—to ensure to every single
patient. This has forced them to ponder, for the first time,
what meaning they attach to the notion of minimum
essential healthcare, and how to make the collocation of
limited resources socially and ethically acceptable.
The reliance on technical dimensions such as effectivity
and cost-effectivity that characterized priority-setting in
Europe until the beginning of the Nineties reflected an
attempt by policy-makers to avoid directly addressing ethi-
cal choices (Martin and Benatar 2008). Such an approach is
only consistent with one ethical dimension at most, the
utilitarian one, and incompletely so, as it does not necessarily
take into account the aggregate gain of the population.
The subsequent evolution has seen the gradual diffusion
of the notion of equality as implied by the principle of
solidarity, both in terms of contractual/risk solidarity and in
terms of humanitarian solidarity (Hoedemaekers and
Dekkers 2003). This notion of equality represents a step
forward relative to previously common forms of equality
that did not explicitly reflect a clear ethical standpoint: for
instance, the principle of ‘‘avoiding the worst outcome’’
typical of medical triage and the one of ‘‘avoiding undue
burdens’’ that justifies the decision to exempt the immu-
nocompromised from inoculation of some vaccines already
contained elements of egalitarianism and solidarity, while
the provision of services and public goods of vital impor-
tance to well-being implicitly reflected a communitarian
viewpoint (Rhodes 2008).
In fact, egalitarianism and solidarity do not represent the
only ethical perspective that has gained ground in this
process. Many European States today appear to embrace
the notion of self-determination of individual typical of
liberalism and that of social functioning typical of com-
munitarianism. The ongoing process should therefore be
considered as a recognition by policy-makers and experts
that considerations of value cannot be avoided when
addressing the issue of resource allocation, priority setting
and definition of essential care—a recognition long called
for by literature in the discipline, in an attempt of which the
UNESCO Report on Social Responsibility is but the most
recent chapter (Hoedemaekers and Dekkers 2003).
The next step in this process, one called for by the
UNESCO Report, will be shifting from a national to an
international and from a European to a global perspective in
the diffusion of good practices for ensuring respect of the
individual choices and values of patients—a shift in per-
spective made necessary by the existing burden of health
inequalities the next few decades will compel us to face.
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